We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

A MicroRNA Elevated in Pancreatic Cancer Patients May Have Diagnostic Potential

By LabMedica International staff writers
Posted on 20 Nov 2013
A microRNA (miRNA) was identified that is present at high levels in the blood of most pancreatic cancer patients and may serve as a diagnostic marker and an indicator of the disease’s aggressiveness.

Statistics from the [US] National Cancer Institute (Bethesda, MD, USA) show that only about 6% of people with pancreatic cancer survive more than five years after diagnosis. In 2013 an estimated 45,220 new cases of pancreatic cancer are expected to be diagnosed with more than 38,460 of the cases being fatal.

MiRNAs are snippets of about 20 nucleotides that block gene expression by attaching to molecules of messenger RNA (mRNA) in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA.

Investigators at Indiana University (Indianapolis, USA) determined miRNA levels in patients with pancreatic ductal adenocarcinoma (PDAC). They found that plasma levels of miR-10b were significantly increased in PDAC patients by comparison with normal controls. Furthermore, increased miR-10b expression in PDAC cells was a marker for disease aggressiveness.

MiR-10b promoted the invasion and growth of pancreatic cancer cells by modulating signaling and gene expression. In particular, miR-10b facilitated abnormal signaling by enhancing EGFR (epidermal growth factor receptor) activity.

Senior author Dr. Murray Korc, professor of cancer research at Indiana University, said, "The presence of miR-10b is like a souped-up car that is more like a tank because of the enhancements. So, for those people with miR-10b, their pancreatic cancer is especially aggressive. And pancreatic cancer is already an aggressive disease without that molecule. Patients with high levels of miR-10b resist chemotherapy more and their disease returns sooner after treatment than those without the molecule."

The study was published in the October 7, 2013, online edition of the journal Oncogene.

Related Links:

[US] National Cancer Institute
Indiana University



New
Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
All-in-One Molecular System
AIO M160

Latest Molecular Diagnostics News

Stool DNA Analysis Tracks Disease Activity in IBD
20 Nov 2013  |   Molecular Diagnostics

Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
20 Nov 2013  |   Molecular Diagnostics

Genomic Testing Program Improves Diagnosis of Congenital Hyperinsulinism
20 Nov 2013  |   Molecular Diagnostics



ADLM